Group of Experts No6 I: Insulin Preparations

The invention also relates to the production of insulin preparations of the aforementioned type.

The invention provides a method of improving the stability of insulin formulations

Novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer that are capable of prolonging the action of insulin preparations are disclosed.

Insulin preparations comprising an insulin compound or a mixture of two or more insulin compounds, a nicotinic compound and arginine.

Dry powder inhaled insulin formulations are disclosed.

Methods of making nanoparticulate insulin compositions, dosage forms containing them, and the use of such formulations in insulin therapy are also described.

Insulins are divided into drugs of short and prolonged action.

Novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer that are capable of prolonging the action of insulin preparations are disclosed.

Stable insulin formulations can be prepared by mixing a monomeric insulin and a soluble acylated insulin analog.

It is necessary to administer insulin preparations.

Insulin preparations comprising a long-acting insulin compound, a fast-acting insulin compound, a nicotinic compound and an amino acid.

Injectable insulin formulations that are capable of modifying the amount of insulin released based on the patient's tissue glucose levels, methods for making and using these formulations are described herein.

A stable, soluble insulin formulations having both a fast and a long action.

Nanoparticulate insulin compositions having effective an average particle size of less than about 5 microns are described.